Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Salirasib
Cat. No.:
OB0225LY-0039
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Salirasib is a specific inhibitor of R-Ras, a small GTPase involved in cell signaling pathways that regulate various cellular processes including proliferation and survival.
Synonym:
Farnesyl thiosalicylic acid; S-Farnesylthiosalicylic acid; FTS; 162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; 2-[(2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; Benzoic acid, 2-[[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]-
CAS No.:
162520-00-5
Compound CID:
5469318
Formula:
C22H30O2S
Formula Weight:
358.54
Specification
Relative Density:
1.05 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Salirasib can be used to inhibit Ras methylation.
Library Information
Targets:
Ras
Receptors:
PPMTase
Pathways:
Autophagy; MAPK; GPCR/G protein
Plate Number:
AOCL-1
Plate Location:
d11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
18.33 mg/mL; 51.13 mM
Water Max Solubility:
<0.1 mg/mL (insoluble)
